Bristol-Myers Squibb Company (BMY)

56.44
NYSE : Health Care
Prev Close 55.77
Day Low/High 55.88 / 56.47
52 Wk Low/High 46.01 / 77.12
Avg Volume 12.67M
Exchange NYSE
Shares Outstanding 1.67B
Market Cap 93.29B
EPS 2.70
P/E Ratio 21.05
Div & Yield 1.56 (2.80%)

Latest News

Cramer: I'll Give You the Key to the Rally

Cramer: I'll Give You the Key to the Rally

You have to keep up with the sector rotations.

Bristol-Myers Squibb Prices $1.5 Billion Of Senior Notes

Bristol-Myers Squibb Prices $1.5 Billion Of Senior Notes

Bristol-Myers Squibb Company (NYSE:BMY) today announced that it has agreed to sell $1.

S&P 500 Trades Lower as Fed Signals Move on Rates 'Fairly Soon'

S&P 500 Trades Lower as Fed Signals Move on Rates 'Fairly Soon'

The S&P 500 holds lower on Wednesday after the Federal Reserve signaled comfort in moving to higher interest rate levels "fairly soon."

Cramer: Is the Market Playing 'The Price Is Wrong'?

Cramer: Is the Market Playing 'The Price Is Wrong'?

These may be uncharted waters, but they're not necessarily expensive.

Cramer: Buyers for Bristol-Myers Are Few and Far Between

Cramer: Buyers for Bristol-Myers Are Few and Far Between

Icahn may have a tough time finding interest in this behemoth.

Jim Cramer Talks Tesla, TJX, Square, Fitbit and National Margarita Day!

Jim Cramer Talks Tesla, TJX, Square, Fitbit and National Margarita Day!

TheStreet's Jim Cramer comments on Wednesday's most talked about stocks.

Dow Turns Positive in Wishy-Washy Trading Ahead of Fed Minutes

Dow Turns Positive in Wishy-Washy Trading Ahead of Fed Minutes

Stocks turn mixed on Wednesday morning as investors await more clarity on interest rates from the Federal Reserve.

Stock Futures Waver as Wall Street Awaits Clarity From the Fed

Stock Futures Waver as Wall Street Awaits Clarity From the Fed

Stock futures waver on Wednesday morning as investors seek more clarity on interest rates from the Federal Reserve.

Wake Up Wall Street: Dow Jones Secures Eighth Straight Day of Gains

Wake Up Wall Street: Dow Jones Secures Eighth Straight Day of Gains

Here are 5 things you must know before the market opens Wednesday.

Toll Brothers Beats Expectations, Icahn Buys Stake in Drug Maker

Toll Brothers Beats Expectations, Icahn Buys Stake in Drug Maker

Toll Brothers TOL says the average price of a home it built declined, due to the cost of building materials.

5 Things You Must Know Before the Market Opens Wednesday

5 Things You Must Know Before the Market Opens Wednesday

U.S. stock futures turn mixed Wednesday after breaking records again in the previous session and ahead of minutes from the Federal Reserve's meeting earlier in February.

Icahn Purchases Stake in Bristol-Myers

Icahn Purchases Stake in Bristol-Myers

Shares of Bristol-Myers Squibb (BMY) jumped over 2% on reports Carl Icahn purchased a position in the company.

Activist Investors Shake Up the Boards at Tiffany & Bristol-Myers Squibb

Activist Investors Shake Up the Boards at Tiffany & Bristol-Myers Squibb

Jana Partners are placing three members on Tiffany's board.

Bristol-Myers Squibb Appoints Three New Independent Directors

Bristol-Myers Squibb Appoints Three New Independent Directors

Bristol-Myers Squibb Company (NYSE:BMY) announced today that it has appointed Robert J.

First Comprehensive Pediatric Hematology-Oncology Initiative Launched In Africa

First Comprehensive Pediatric Hematology-Oncology Initiative Launched In Africa

His Excellency the President Lieutenant General Dr. Seretse Khama Ian Khama of the Republic of Botswana, the Honorable Minister Dorcas Makgato of the Ministry of Health and Wellness, the Bristol-Myers Squibb Foundation,...

Your Burning Biotech Questions Answered

Your Burning Biotech Questions Answered

We explore whether the biotech rally can continue and if Gilead Sciences has bottomed.

Procter & Gamble, Apple, Home Depot: Doug Kass' Views

Procter & Gamble, Apple, Home Depot: Doug Kass' Views

Doug Kass shares his thoughts on Procter & Gamble, and wonders if the market is about to slip its moorings.

Your Burning Biotech Questions Answered

Your Burning Biotech Questions Answered

We explore whether the biotech rally can continue and if Gilead Sciences has bottomed.

Health Care ETF Has Been Ailing

Health Care ETF Has Been Ailing

You might want to review your holdings in the sector.

Biotech Buoyed by Deal Talk

Biotech Buoyed by Deal Talk

M&A activity is in a serious upswing, and here are some names to watch.

U.S. Steel, Universal Display, Bristol-Myers Squibb: 'Mad Money' Lightning Round

U.S. Steel, Universal Display, Bristol-Myers Squibb: 'Mad Money' Lightning Round

Jim Cramer is bullish on United States Steel and Universal Display, less so with Arconic and Himax Technologies.

Game Plan for the Week Ahead: Cramer's 'Mad Money' Recap (Friday 2/10/17)

Game Plan for the Week Ahead: Cramer's 'Mad Money' Recap (Friday 2/10/17)

Investors should keep an eye on interest rates and oil, but remember next week is still a week of big earnings reports, says Jim Cramer.

Here's How the Tom Price Stock Portfolio Is Performing Now That He Is Confirmed

Here's How the Tom Price Stock Portfolio Is Performing Now That He Is Confirmed

Tom Price will now head the Department of Health and Human Services.

Cramer: Allergan Is the New Pharma Growth Stock

Cramer: Allergan Is the New Pharma Growth Stock

Jim Cramer compares Allergan's growth to other pharma stocks.

Bristol-Myers Squibb To Take Part In Leerink 6th Annual Global Health Care Conference

Bristol-Myers Squibb To Take Part In Leerink 6th Annual Global Health Care Conference

Bristol-Myers Squibb Company (NYSE:BMY) will take part in the Leerink Annual Global Health Care Conference on Wednesday, February 15, 2017, in New York.

Lower Valuations Have Merck Looking 'Very Hard' at M&A Options

Lower Valuations Have Merck Looking 'Very Hard' at M&A Options

On an earnings call, Merck CEO Kenneth Frazier said the company will continue to seek opportunities with a particular focus on augmenting its early- to mid-stage pipeline.

Cancer Survivors Need More Efficient Integrated Long-Term Care And Stronger Policies Across Healthcare, Advocacy And The Workplace, New Research Concludes

Cancer Survivors Need More Efficient Integrated Long-Term Care And Stronger Policies Across Healthcare, Advocacy And The Workplace, New Research Concludes

As more patients are living longer with cancer, multi-stakeholder-driven changes are required to improve integrated, or coordinated, care that addresses the range of their long-term needs, according to a new Bristol-Myers...